Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT.
about
Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Palifermin does not influence ...... ical diseases undergoing HSCT.
@en
Palifermin does not influence ...... ical diseases undergoing HSCT.
@nl
type
label
Palifermin does not influence ...... ical diseases undergoing HSCT.
@en
Palifermin does not influence ...... ical diseases undergoing HSCT.
@nl
prefLabel
Palifermin does not influence ...... ical diseases undergoing HSCT.
@en
Palifermin does not influence ...... ical diseases undergoing HSCT.
@nl
P2093
P356
P1476
Palifermin does not influence ...... gical diseases undergoing HSCT
@en
P2093
Agnieszka Tomaszewska
Andrzej Hellman
Barbara Nasilowska-Adamska
Bozena Marianska
Jerzy Holowiecki
Maria Bieniaszewska
Mieczyslaw Komarnicki
Piotr Rzepecki
Richard Szydlo
P356
10.12659/AOT.882218
P577
2011-10-01T00:00:00Z